Corcept Therapeutics | CORT - Operating Expenses


Corcept Therapeutics reported $197.64M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
Alaunos Therapeutics USD 1.19M 148K Sep/2025
ANI Pharmaceuticals USD 217.93M 287.88M Dec/2025
Ardelyx USD 120.12M 14.46M Dec/2025
Assertio Holdings USD 105.8M 12.5M Sep/2025
Aurora Cannabis CAD 129.98M 16.05M Dec/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Canopy Growth CAD 87.2M 6.22M Dec/2025
Corcept Therapeutics USD 197.64M 219K Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
J&J USD 18.97B 2.38B Dec/2025
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
Merck USD 10.16B 558M Dec/2025
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Novartis USD 9.8B 61M Dec/2025
Novartis USD 9.8B 23M Dec/2025
Omeros USD 59.16M 20.13M Jun/2024
Pacira USD 193.68M 27.32M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
Supernus Pharmaceuticals USD 197.75M 54.54M Dec/2025
TG Therapeutics USD 142.08M 9.74M Dec/2025